Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor

Cytokine

Volumn 8, Issue 6, 1996, Pages 482-487

  Eliaz, Rom ^a   Wallach, David ^b   Kost, Joseph ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Chronic inflammation; Controlled release; Cytokines; Soluble receptors; TNF

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CHRONIC INFLAMMATION; HUMAN; INFLAMMATORY DISEASE; LONG TERM EXPOSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030176045     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0065     Document Type: Article

References (35)

1. 1. Beutler B, Cerami A (1988) Tumor necrosis factor, cachexia, shock and inflammation: a common mediator. Annu Rev Biochem 57:505-518.
2. 2. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452.
3. 3. Olsson I, Lantz M, Nilsson. E, Peetre C, Thysell H, Grubb A, Adolf G (1989) Isolation and characterization of a tumor necrosis binding protein from urine. Eur J Haematol 42:270-275.
4. 4. Seckinger P, Isaaz S, Dayer JM (1989) Purification and biologic characterization of a specific tumor necrosis factor α inhibitor. J Biol Chem 264:11966-11973.
5. 5. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974-11980.
6. 6. Engelmann H, Novick D, Wallach D (1990) Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531-1536.
7. 7. Kalinkovich A, Engelmann H, Harpaz N, Burstein R, Barak V, Kalickman I, Wallach D, Bentwich Z (1992) Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 89: 351-355.
8. 8. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160-1169.
9. 9. Lanz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor causes an increase in circulating TNF-binding proteins in humans. Cytokine 2:402-406.
10. 10. Aderka D, Wysenbeek AJ, Cope A, Engelmann H, Molad Y, Hornik V, Levo Y, Feldmann M, Wallach D (1993) Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthr Rheum 38:1111-1120.
11. 11. Aderka D, Engelmann H, Wallach D (1993) Soluble Tumor Necrosis Factor Receptors in Health and Disease. In Fiers W (ed) Tumor Necrosis-Factor: Molecular and Cellular Biology and Clinical Relevance. vol. IV S. Karger, Basel, pp 191-198.
12. 12. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA (1993) Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignacy. Eur Cytokine Netw 4:169-180.
13. 13. Bemelmans MH, Gouma DJ, Buurman WA (1993) LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol 151:5554-5562.
14. 14. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD (1994) Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96:146-151.
15. 15. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman C (1995) Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 102:20-25.
16. 16. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329.
17. 17. Rhine, WD, Hsieh, ST, Langer R (1980) Polymers for sustained macromolecules release: procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci 69:265-270.
18. 18. Kost J, Noecker R, Kunica E, Langer R (1985) Magnetically controlled release systems: effect of polymer composition. J Biomed Mater Res 19:935-940.
19. 19. Murray J, Brown L, Langer R (1984) Controlled release of microquantities of macromolecules. Cancer Drug Deliv 1:119-123.
20. 20. Beck LR, Pope VZ, Cowsar DR, Lewis DH, Tice TR (1980) Evaluation of a new three month contraceptive microsphere system in primates. J Contracept Deliv Syst 1:79-82.
21. 21. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Viocolo G, Wolfe A, Socher SH (1987) Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555-563.
22. 22. Korn JH, Mory Y, Ziberstein A, Holtmann H, Revel M, Wallach D (1988) Cloning of genomic DNA for tumor necrosis factor and efficient expression in CHO cells. Lymphokine Res 7:349-358.
23. 23. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumor necrosis factor in a predictive genetic model of arthritis. EMBO J 10:4025-4031.
24. 24. Probert L., Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G (1993) Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immum 151:1894-1906.
25. 25. Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G (1991) Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602-5607.
26. 26. Gascon MP, Porchet HC, Le CJ, Ythier A, Wallach D, Piguet PF, Grau GE (1992) Pharmacokinetics and tissue distribution of human urinary tumor necosis factor binding protein in mice. Drug Metab Dispos Biol Fate Chem 20:592-595.
27. 27. Brennan FM, Maini RN, Feldmann M (1992) TNF alpha-a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-298.
28. 28. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH (1991) Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88:10535-10539.
29. 29. Tilg H, Shapiro L, Atkins MB, Dinarello CA, Mier JW (1993) Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 151:3299-3307.
30. 30. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561.
31. 31. Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A (1994) Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol 152:1347-1358.
32. 32. Howard OM, Clouse KA, Smith C, Goodwin RG, Farrer WL (1993) Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 90:2335-2339.
33. 33. Loetscher H, Angehrn P, Schlaeger EJ, Gentz R, Lesslaur W (1993) Efficacy of a chimeric TNFR-IgG fusion protein to inhibit TNF activity in animal models of septic shock. In Levin J, Alving CR, Munford RS, Shütz PL (eds) Bacterial endotoxin: Recognition and effector mechanisms. Elsevier Sceince Publishers B. V., Amsterdam, pp 455-462.
34. 34. Fernandez-Botran R (1991) Soluble cytokine receptors: their role in immunoregulation FASEB J 5:2567-2574.
35. 35. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300:281-290.